ARCA biopharma, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>ARCA biopharma, Inc. (ORKA) has filed its 2023 annual report (10-K) detailing its financial performance and business operations.</b>

AI Summary

ARCA biopharma, Inc. (ORKA) filed a Annual Report (10-K) with the SEC on February 1, 2024. ARCA biopharma, Inc. (ORKA) filed its 2023 Form 10-K on February 1, 2024. The company was formerly known as NUVELO INC and HYSEQ INC. ARCA biopharma operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is in Westminster, Colorado.

Why It Matters

For investors and stakeholders tracking ARCA biopharma, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of ARCA biopharma's financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. Understanding the details within this filing, such as executive compensation, risk factors, and financial statements, is essential for stakeholders to make informed investment decisions regarding ARCA biopharma (ORKA).

Risk Assessment

Risk Level: medium — ARCA biopharma, Inc. shows moderate risk based on this filing. The company operates in the biopharmaceutical sector, which is inherently risky due to long development cycles, regulatory hurdles, and high failure rates in clinical trials, as indicated by its industry classification and the nature of 10-K filings.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to understand potential challenges and opportunities for ARCA biopharma (ORKA).

Key Numbers

• 2023-12-31 — Fiscal Year End (FISCAL YEAR END)
• 2024-02-01 — Filing Date (FILED AS OF DATE)
• 0000907654 — Central Index Key (CENTRAL INDEX KEY)
• 000-22873 — SEC File Number (SEC FILE NUMBER)

Key Players & Entities

• ARCA biopharma, Inc. (company) — COMPANY CONFORMED NAME
• ORKA (company) — tk
• NUVELO INC (company) — FORMER COMPANY
• HYSEQ INC (company) — FORMER COMPANY
• 2023-12-31 (date) — CONFORMED PERIOD OF REPORT
• 2024-02-01 (date) — FILED AS OF DATE
• Westminster, CO (location) — BUSINESS ADDRESS CITY, STATE
• 7209402200 (phone) — BUSINESS PHONE

Forward-Looking Statements

• ARCA biopharma will continue to manage its capital structure actively, potentially through further equity raises or share repurchases. (ARCA biopharma, Inc.) — medium confidence, target: 2024-12-31
• The company may see further changes in executive compensation or leadership roles as it navigates its strategic objectives. (srt:ChiefExecutiveOfficerMember) — medium confidence, target: 2024-12-31

FAQ

Industry Context

ARCA biopharma operates within the biopharmaceutical industry, specifically focusing on 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'. This sector is characterized by significant research and development, regulatory oversight, and the potential for high-impact medical advancements.

Regulatory Implications

As a biopharmaceutical company, ARCA biopharma is subject to stringent regulations from bodies like the FDA concerning drug development, testing, and approval processes. Compliance with these regulations is critical for market access and product viability.

What Investors Should Do

1. Analyze the financial statements within the 10-K to assess ARCA biopharma's revenue, expenses, and profitability for FY 2023.
2. Review the 'Risk Factors' section to understand potential challenges and threats to ARCA biopharma's business operations and future growth.
3. Examine any disclosures related to executive compensation and corporate governance to evaluate management's alignment with shareholder interests.

Key Dates

• 2024-02-01: 10-K Filing — Filing of the annual report for the fiscal year ended December 31, 2023.

Year-Over-Year Comparison

This is the initial filing analyzed for ARCA biopharma, Inc. (ORKA) in this format, so no prior period comparison is available.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABIO Nasdaq Capital Marke
• $31 b — nited States was estimated to be nearly $31 billion, of which two-thirds, or over $20
• $20 b — 1 billion, of which two-thirds, or over $20 billion, was attributable to direct medic
• $6.0 billion — ed that AF costs the U.S. economy about $6.0 billion annually. AF and HF share many of the

Filing Documents

• abio-20231231.htm (10-K) — 2010KB
• abio-ex19.htm (EX-19) — 104KB
• abio-ex23_1.htm (EX-23.1) — 3KB
• abio-ex31_1.htm (EX-31.1) — 12KB
• abio-ex31_2.htm (EX-31.2) — 12KB
• abio-ex32_1.htm (EX-32.1) — 10KB
• abio-ex97.htm (EX-97) — 46KB
• 0000950170-24-009809.txt (&nbsp;) — 6408KB
• abio-20231231.xsd (EX-101.SCH) — 876KB
• abio-20231231_htm.xml (XML) — 737KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 15 Item 1B. Unresolved Staff Comments 40 Item 1C. Cybersecurity 40 Item 2.

Properties

Properties 40 Item 3.

Legal Proceedings

Legal Proceedings 40 Item 4. Mine Safety Disclosures 40 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 41 Item 6. Reserved 41 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 47 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 48 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, KPMG LLP 49 BALANCE SHEETS 50 51 52 53

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS 54 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 65 Item 9A.

Controls and Procedures

Controls and Procedures 65 Item 9B. Other Information 65 Item 9C. D isclosu r e Regarding Foreign Jurisdictions that Prevent Inspections 65 PART III Item 10. Directors, Executive Officers and Corporate Governance 66 Item 11.

Executive Compensation

Executive Compensation 73 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 79 Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant Fees and Services 83 PART IV Item 15. Exhibits and Financial Statement Schedules 84

SIGNATURES

SIGNATURES 88 PART I I tem 1. Business Some of the statements under "Business," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this Annual Report constitute forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of these statements include, but are not limited to, statements regarding the following: potential future development plans for Gencaro our ability to secure sufficient financing to support any clinical trials for Gencaro, the likelihood that any Phase 3 clinical trial results for Gencaro will satisfy the requirements of our Special Protocol Assessment agreement, our likelihood to enter into an acquisition, merger, business combination or other strategic transaction, the expected features and characteristics of Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, or AF, future treatment options for patients with AF, the potential for Gencaro to be the first genetically-targeted AF prevention treatment, statements regarding potential Phase 3 development plans for Gencaro, including the timing and results thereof, and the ability of ARCA's financial resources to support its operations at the current levels through the middle of fiscal year 2025, our ability to obtain additional funding when needed or enter into a strategic or other transaction, the extent to which our issued and pending patents may protect our products and technology, the potential of such product candidates to lead to the development of safe or effective the

View Full Filing

View this 10-K filing on SEC EDGAR